Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
S. N. Tereshchenko,
M. V. Shestakova,
F. T. Ageev,
G. R. Galstyan,
A. S. Galyavich,
M. G. Glezer,
I. V. Zhirov,
Yu. A. Karpov,
Zh. D. Kobalava,
S. T. Matskeplishvili https://doi.org/10.15829/1560-4071-2020-3919
Abstract
Relationships and Activities. The Council of Experts was supported by AstraZeneca.
About the Authors
S. N. Tereshchenko
National Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical Education
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
M. V. Shestakova
National Medical Research Center for Endocrinology
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
F. T. Ageev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
G. R. Galstyan
National Medical Research Center for Endocrinology
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
A. S. Galyavich
Kazan State Medical University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
M. G. Glezer
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
I. V. Zhirov
National Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical Education
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
Yu. A. Karpov
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
Zh. D. Kobalava
Peoples’ Friendship University of Russia
Russian Federation
Competing Interests: not
Russian Federation
Moscow
Competing Interests: not
S. T. Matskeplishvili
Medical Research and Educational Center. Moscow State University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
References
1. McMurray JJV, DeMets DL, Inzucchi SE, et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure. 2019;21(11). doi:10.1002/ejhf.1548.
2. McMurray JJV, Solomon S, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. Mass Medical Soc. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.
3. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF Trial. Circulation. 2019;141:90-9. doi:10.1161/CIRCULATIONAHA.119.044138.
4. FARXIGA® (dapagliflozin) [Prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; ЛП-002596 2412.2019. (In Russ.)
5. Mareev VY, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Goidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:1018087/cardio.2475.
6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;18(8):891-975. doi:101093/eurheartj/ehw128.
7. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 2002;347:1397-402. doi:10.1056/NEJMoa020265.
8. Orso F, Fabbri G, Maggioni AP. Epidemiology of heart failure. Handb Exp Pharmacol. 2017;243:15-33. doi :101007/164_2016_74.
9. Arutyunov AG, Rylova AK, Arutyunov GP. Register of hospitalized patients with circulatory decompensation (register of Pavlovsk hospital). Report. 2. The clinical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with circulatory decompensation. Heart failure journal. 2014;15,2:67-75. (In Russ.)
10. Mareev YV, Gerasimova VV, Gorynova TV, et al. Factors determining the prognosis for chronic heart failure: the role of the width and morphology of the QRS complex. Heart failure journal. 2012;13,5:255-66. (In Russ.)
11. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose ^transporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016 Sep 6;134(10):752-72. doi:10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
12. The American Journal of Managed Care. FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes. 2020. https://www.ajmc.com/newsroom/fda-grants-dapagliflozin-priority-review-for-heart-failure-even-for-those-without-diabetes (дата обращения 27.04.2020).
13. Standards of specialized diabetes care. Ed. Dedov II, Shestakova MV, Mayorov AYu. 9th Edition; 2019. Moscow: UP PRINT, 2019. ISBN: 978-5-91487-136-6. (In Russ.) doi:10.14341/DM221S1.
Review
For citations:
Tereshchenko S.N., Shestakova M.V., Ageev F.T., Galstyan G.R., Galyavich A.S., Glezer M.G., Zhirov I.V., Karpov Yu.A., Kobalava Zh.D., Matskeplishvili S.T. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology. 2020;25(5):3919. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3919
Views:
4342
Email this article 